$COR

Krikorian Lazarus sold $321K of COR

Krikorian Lazarus (SVP & Chief Accounting Officer) sold 985 shares of Cencora, Inc. (COR) at $325.97 ($0.32M total) on 2026-09-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Krikorian Lazarus
Published Sep 2, 2026, 8:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 2, 2026, 8:30 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$COR
Neutral
medium confidence
Mentioned
$COR
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CORNeutralLow
01

Why it matters

The sale is modest and unlikely to affect market perception, but it provides transparency for investors.

02

Market read

Routine insider transaction with limited trading relevance.

03

What to watch

Potential upcoming earnings or guidance releases could change the impact of this sale.

Relevance 3/10Novelty 3/10Timing: post‑market 2026‑09‑02

Background

SEC Form 4 filing discloses an insider's open‑market sale under a 10b5‑1 plan.

Company-level read

Ticker impact

$CORNeutralMedium confidence
Context

SVP & Chief Accounting Officer sold 985 shares for $321,080 via a 10b5‑1 plan on 2026‑09‑01

Expected impact

minimal downward pressure, unlikely to move price materially

Evidence & confidence

The sale amount is modest relative to total holdings and market cap; insider is executing a pre‑arranged plan.

Market effects

None; the transaction is company‑specific and does not affect the broader healthcare distribution sector.

None; the filing is U.S.‑focused with no regional spillover.

None; the event is limited to Cencora shareholders.

Counterpoint

If the insider sale signals concerns about upcoming challenges, a short‑term dip could be amplified.

Key entities

  • Krikorian Lazarus

    SVP & Chief Accounting Officer of Cencora, Inc.

  • Cencora, Inc.

    U.S. pharmaceutical distribution company (ticker COR).

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

HighAI 9/10

Cencora Agrees to Take Controlling Stake in American Oncology Network in $2.4 Billion Deal Spanning 21 States

Cencora agreed to acquire American Oncology Network (AON) for $2.4 billion, expanding its oncology services. The deal, pending approval, includes $2.3 billion at closing plus up to $100 million in contingent value rights. Cencora already owns 4% of AON and aims to increase its stake to 75%. The acquisition is part of a broader trend of drug wholesalers buying cancer practice management companies.

$CORHighAI 9/10

Cencora to buy American Oncology Network in $2.4bn deal

Cencora (COR) agreed to acquire American Oncology Network (AON) for $2.4bn, including $2.3bn at closing and up to $100m in contingent value rights. COR shares fell 4.84% post-announcement, despite recent gains. The deal expands COR's oncology services into 12 new states. COR raised its fiscal 2026 EPS guidance to at least $17.90. The transaction requires regulatory approval and AON stockholder approval.

$CORHighAI 9/10

Cencora, Inc. (COR): Results of Operations and Financial Condition

Cencora, Inc. (COR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 CENCORA TO ACQUIRE AMERICAN ONCOLOGY NETWORK TO STRENGTHEN SUPPORT OF COMMUNITY ONCOLOGY Builds on Cencora’s MSO platform by adding complementary capabilities and expanding presence across twelve additional states CONSHOHOCKEN, PA & FORT MYERS, Fla., October 21, 2026

$CORHighAI 9/10

Cencora to acquire American Oncology Network for $2.4 billion

Cencora Inc. (NYSE:COR) will acquire American Oncology Network Inc. (OTCQX:AONC) for $2.4 billion, including $2.3 billion at closing and up to $100 million in contingent value rights. The deal will expand Cencora's oncology services platform. Cencora expects the acquisition to be accretive to earnings per share by the second year post-closing and updated its 2026 EPS guidance to at least $17.90. The transaction is subject to regulatory approvals and AON stockholder approvals.

$CORHighAI 9/10

Cencora, Inc. (COR) to Acquire American Oncology Network for $2.4B EV

Cencora (COR) agreed to acquire American Oncology Network for $2.4B EV, with $2.3B paid at closing and up to $100M in contingent value rights. Cencora expects to pay about $1.7B for 75% ownership if 25% equity is rolled. The deal is expected to be EPS accretive in year two, subject to approvals. According to Cencora, the acquisition aligns with its strategy to expand in oncology services.

HighAI 8/10

Cancer-practice support would expand to 12 more states under Cencora's planned acquisition

Cencora plans to acquire American Oncology Network (AON), expanding its oncology services to 12 more states. The deal aims to enhance care access and support independent practices. Cencora expects the acquisition to be accretive to its adjusted diluted EPS in the second year post-closing. The transaction is subject to regulatory approvals and AON stockholder approvals.